MX2009004244A - Derivados de pteridina como inhibidores de cinasa tipo polo utiles en el tratamiento de cancer. - Google Patents

Derivados de pteridina como inhibidores de cinasa tipo polo utiles en el tratamiento de cancer.

Info

Publication number
MX2009004244A
MX2009004244A MX2009004244A MX2009004244A MX2009004244A MX 2009004244 A MX2009004244 A MX 2009004244A MX 2009004244 A MX2009004244 A MX 2009004244A MX 2009004244 A MX2009004244 A MX 2009004244A MX 2009004244 A MX2009004244 A MX 2009004244A
Authority
MX
Mexico
Prior art keywords
optionally substituted
ring
polo
treatment
alkyl
Prior art date
Application number
MX2009004244A
Other languages
English (en)
Spanish (es)
Inventor
Stephen John Davies
Sanjay Ratilal Patel
David Festus Charles Moffat
Kenneth William John Baker
Oliver James Philps
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0621205A external-priority patent/GB0621205D0/en
Priority claimed from GB0715614A external-priority patent/GB0715614D0/en
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Publication of MX2009004244A publication Critical patent/MX2009004244A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2009004244A 2006-10-25 2007-10-19 Derivados de pteridina como inhibidores de cinasa tipo polo utiles en el tratamiento de cancer. MX2009004244A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0621205A GB0621205D0 (en) 2006-10-25 2006-10-25 Inhibitors of PLK
GB0715614A GB0715614D0 (en) 2007-08-10 2007-08-10 Inhibitors of plk
PCT/GB2007/003998 WO2008050096A1 (en) 2006-10-25 2007-10-19 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2009004244A true MX2009004244A (es) 2009-05-14

Family

ID=38896021

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004244A MX2009004244A (es) 2006-10-25 2007-10-19 Derivados de pteridina como inhibidores de cinasa tipo polo utiles en el tratamiento de cancer.

Country Status (13)

Country Link
US (1) US20100216802A1 (https=)
EP (1) EP2079743B1 (https=)
JP (1) JP2010507639A (https=)
KR (1) KR20090071668A (https=)
AT (1) ATE542820T1 (https=)
AU (1) AU2007310604B2 (https=)
BR (1) BRPI0718120A2 (https=)
CA (1) CA2665736A1 (https=)
EA (1) EA200900593A1 (https=)
IL (1) IL198082A0 (https=)
MX (1) MX2009004244A (https=)
NZ (1) NZ577153A (https=)
WO (1) WO2008050096A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
WO2008053131A1 (en) * 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
CN101646671A (zh) 2006-12-14 2010-02-10 弗特克斯药品有限公司 用作蛋白激酶抑制剂的化合物
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0807451D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
MX2011000021A (es) * 2008-06-23 2011-02-24 Vertex Pharma Inhibidores de proteina cinasas.
AU2009271658B2 (en) 2008-06-23 2014-04-10 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
AU2010291834A1 (en) * 2009-09-04 2012-03-15 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
PL3222616T3 (pl) 2012-10-17 2019-12-31 Macrophage Pharma Limited N-[2-{4-[6-amino-5-(2,4-difluorobenzoilo)-2-oksopirydyn-1(2h)-ylo]-3,5-difluorofenylo}etylo)-L-alaninian tert-butylu lub jego sól, hydrat lub solwat
EP2961403A4 (en) 2013-03-01 2016-11-30 Zalicus Pharmaceuticals Ltd HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
MX2016009975A (es) * 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de dihidropteridinona y sus usos.
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
EP3347021A4 (en) 2015-09-11 2019-07-24 Dana-Farber Cancer Institute, Inc. CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
WO2020033823A1 (en) * 2018-08-10 2020-02-13 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
CN111039944B (zh) * 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 Mst1激酶抑制剂及其用途
KR102260995B1 (ko) * 2018-11-28 2021-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
CN115947728B (zh) * 2021-10-09 2024-01-09 沈阳药科大学 含磺酰基的二氢喋啶酮衍生物及其应用
US20230263783A1 (en) 2022-02-18 2023-08-24 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization
CN118047779B (zh) * 2022-11-09 2025-02-11 沈阳药科大学 含苯联杂芳基的二氢喋啶酮衍生物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1786817A1 (de) * 2004-08-26 2007-05-23 Boehringer Ingelheim International GmbH Pteridinone als plk (polo like kinase) inhibitoren
WO2006021548A1 (de) * 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel

Also Published As

Publication number Publication date
EP2079743B1 (en) 2012-01-25
EA200900593A1 (ru) 2010-06-30
BRPI0718120A2 (pt) 2013-11-12
CA2665736A1 (en) 2008-05-02
IL198082A0 (en) 2009-12-24
NZ577153A (en) 2012-02-24
US20100216802A1 (en) 2010-08-26
JP2010507639A (ja) 2010-03-11
AU2007310604A1 (en) 2008-05-02
ATE542820T1 (de) 2012-02-15
WO2008050096A1 (en) 2008-05-02
AU2007310604B2 (en) 2012-02-02
EP2079743A1 (en) 2009-07-22
KR20090071668A (ko) 2009-07-01

Similar Documents

Publication Publication Date Title
MX2009004244A (es) Derivados de pteridina como inhibidores de cinasa tipo polo utiles en el tratamiento de cancer.
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
NZ597983A (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
BR0316146A (pt) Derivados de amida do ácido 3-(2-hidróxifenil)-1h-pirazol-4-carboxìlico como inibidores de hsp90 para o tratamento de câncer
TNSN07281A1 (en) Pyrazole derivatives for the inhibition of cdk's and gsk's
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
MX2008013583A (es) Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
PL1678166T3 (pl) Inhibitory kinaz białkowych
MX2011007499A (es) Derivados de pirimidin-carboxamida como inhibidores de la cinasa syk.
TN2010000131A1 (en) Polo-like kinase inhibitors
MY146420A (en) Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
UA95976C2 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
MX2011009146A (es) Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2011011516A (es) Compuestos farmaceuticos.
PE20090216A1 (es) Compuestos triazolil aminopirimidina
MX2009008386A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer.
WO2007134827A8 (en) 5-phenyl-thiaz0l-2-yl-urea derivatives and use as pi3 kinase inhibitors
PH12018502411A1 (en) Novel 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one derivative
WO2006123165A3 (en) Pyrimidine derivatives as hsp90 inhibitors
NZ592392A (en) PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
MY155959A (en) Use of indole derivatives as nurr-1 activators for treating parkinson's disease.
WO2008110690A3 (fr) Nouveaux derives indoliques, leurs procedes de preparation et leurs utilisations notamment en tant qu'antibacteriens
MX2010005787A (es) Derivados de imizado-tiazole en la forma de inhibidores de cinasa de proteina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal